Xiaodong Cheng
Professor and Chairman
Department of Patient Care
Unit Bolzano Regional Hospital
Austria
Biography
Dr. Cheng is a Professor in the Department of Pharmacology and Toxicology at the University of Texas Medical Branch and Deputy Director of the NIEHS funded Center in Environmental Toxicology at UTMB. He is also a member of the Sealy Center of Cancer Cell Biology Sealy Center of Structural Biology and Molecular Biophysics and Center for Addiction Research. He received his PhD in Biochemistry and Molecular Biology at the University of Texas Medical Branch in 1994 and completed a postdoctoral fellowship in biochemistry under Professor Susan Taylor from University of California in San Diego in 1999. Dr. Cheng is a recipient of an American Cancer Society Research Scholar Award. He has also received the HUPO 3rd World Congress Young Scientist Award in 2004. Dr. Cheng currently serves as an Editor for Acta Biochimica et Biophysica Sinica and is on the Editorial Boards of Frontiers in Bioscience and The Open Proteomics Journal. Dr. Cheng is a Professor in the Department of Pharmacology and Toxicology at the University of Texas Medical Branch and Deputy Director of the NIEHS funded Center in Environmental Toxicology at UTMB. He is also a member of the Sealy Center of Cancer Cell Biology Sealy Center of Structural Biology and Molecular Biophysics and Center for Addiction Research. He received his PhD in Biochemistry and Molecular Biology at the University of Texas Medical Branch in 1994 and completed a postdoctoral fellowship in biochemistry under Professor Susan Taylor from University of California in San Diego in 1999. Dr. Cheng is a recipient of an American Cancer Society Research Scholar Award. He has also received the HUPO 3rd World Congress Young Scientist Award in 2004. Dr. Cheng currently serves as an Editor for Acta Biochimica et Biophysica Sinica and is on the Editorial Boards of Frontiers in Bioscience and The Open Proteomics Journal.
Research Interest
Dr. Cheng\\\\\\\'s research program focuses on using multidisciplinary approaches, coupling biochemistry and biophysics with cell biology and pharmacology, to understand the structure and function of exchange protein directly activated by cAMP (Epac) and oncogene KRAS. Our long-term goals are to unravel the signaling intricacies of Epac and KRAS and to design pathway specific inhibitors for these important signaling molecules so that their functions can be pharmaceutically exploited and modulated for the treatment of human diseases.
